Representing Danaher Corporation ("Danaher") in the Korean merger filing for its acquisition of GE Healthcare Life Sciences’ Biopharma business, Kim & Chang obtained timely clearance for the transaction from the Korea Fair Trade Commission (the “KFTC”) on condition of divestiture of a few businesses.

As one of the largest mergers in the biopharma industry, particularly between major global players, the case involved an in-depth and detailed analysis and competitive assessment of a large number of product markets. 

Based on a comprehensive understanding of the relevant industry as well as its expertise in complicated competitive assessment, Kim & Chang assisted the KFTC’s understanding of the products involved and explained a set of remedies that would effectively address potential concerns that may arise.

By promptly responding and efficiently collaborating with the KFTC in providing necessary information to expedite the review process, Kim & Chang was able to convince the KFTC that there would be no significant anti-competitive impact on the Korean market, other than those addressed by a remedy proposal made by Danaher.